Neuromotor dysfunction in early psychosis

Annals of Clinical Psychiatry

Volumn 14, Issue 2, 2002, Pages 113-121

  Whitehorn, David ^a,b   Kopala, Lili C ^b  

^a Nova Scotia Early Psychosis Program   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Evaluation scales: AIMS, SAS, Barnes Akathisia Scale, ESRS, NES, HNTT; Extrapyramidal signs and symptoms (EPSS); Neuroleptics; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

DISEASE COURSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RATING SCALE; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SYNDROME; TIME FACTORS;

EID: 0036592643     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016859005849     Document Type: Review

References (61)

1. The dose-response relationship for memory impairment by anticholinergic drugs
2. Memory impairment in schizophrenia: Perspectives from psychopathology and pharmacotherapy
3. Tardive dyskinesia
4. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone
5. Is neuroleptic dysphoria a healthy response?
6. Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome
7. Parkinson's disease
8. Huntington's disease
9. Models of basal ganglia function and pathophysiology of movement disorders
10. How to examine patients using the Abnormal Involuntary Movement Scale
11. A rating scale for drug-induced akathisia
12. A rating scale for extrapyramidal side effects
13. Extrapyramidal symptom rating scale
14. The Neurological Evaluation Scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia
15. Inter-rater reliability of the neurological examination in schizophrenia
16. The handwriting test as an aid to neuroleptic dosage
17. Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs
18. Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics
19. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
20. Serotonin-dopamine interaction and its relevance to schizophrenia
21. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
22. Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study
23. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose
24. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
25. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
26. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis
27. Atypical antipsychotics: Mechanism of action
28. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
29. Risperidone in the treatment of schizophrenia
30. Extrapyramidal symptoms in patients treated with risperidone
31. Clinical experience in developing treatment regimens with the novel antipsychotic risperidone
32. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia
33. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality
34. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
35. Assessment of EPSS and tardive dyskinesia in clinical trials
36. Neurotransmitter interactions in schizophrenia-therapeutic implications
37. Spontaneous and drug-induced movement disorders in schizophrenia
38. Parkinsonism in neuroleptic naïve schizophrenic patients
39. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
40. Risk factors for spontaneous dyskinesia in schizophrenia
41. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone
42. Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapyramidal signs
43. Basal ganglia volumes and treatment-response in never-medicated, first-episode schizophrenia patients
44. Decreased caudate volume in neuroleptic-naïve psychotic patients
45. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone
46. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics
47. Schizophrenia, psychosis, and the basal ganglia
48. The basal ganglia and cognitive pattern generators
49. What are the functional consequences of neurocognitive deficits in schizophrenia?
50. Functional magnetic resonance imaging evidence for disrupted basal ganglia function in schizophrenia
51. "cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry?
52. Recalling word lists reveals "cognitive dysmetria" in schizophrenia: A positron emission tomography study
53. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus
54. Canadian clinical practice guidelines for the treatment of schizophrenia
55. Practice guideline for the treatment of patients with schizophrenia
56. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
57. Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade